These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 35593031)

  • 21. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
    Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
    AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
    Hauser A; Goldstein F; Reichmuth ML; Kouyos RD; Wandeler G; Egger M; Riou J
    J Clin Epidemiol; 2022 Aug; 148():135-145. PubMed ID: 35192922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.
    Ndahimana Jd; Riedel DJ; Mwumvaneza M; Sebuhoro D; Uwimbabazi JC; Kubwimana M; Mugabo J; Mulindabigwi A; Kirk C; Kanters S; Forrest JI; Jagodzinski LL; Peel SA; Ribakare M; Redfield RR; Nsanzimana S
    Trop Med Int Health; 2016 Jul; 21(7):928-35. PubMed ID: 27125473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
    Meriki HD; Tufon KA; Anong DN; Atanga PN; Anyangwe IA; Cho-Ngwa F; Nkuo-Akenji T
    PLoS One; 2019; 14(11):e0225575. PubMed ID: 31751428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries.
    Crowell TA; Danboise B; Parikh A; Esber A; Dear N; Coakley P; Kasembeli A; Maswai J; Khamadi S; Bahemana E; Iroezindu M; Kiweewa F; Owuoth J; Freeman J; Jagodzinski LL; Malia JA; Eller LA; Tovanabutra S; Peel SA; Ake JA; Polyak CS;
    Clin Infect Dis; 2021 Oct; 73(7):e2311-e2322. PubMed ID: 32785695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
    Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
    PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
    TenoRes Study Group
    Lancet Infect Dis; 2016 May; 16(5):565-575. PubMed ID: 26831472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.
    Hosseinipour MC; van Oosterhout JJ; Weigel R; Phiri S; Kamwendo D; Parkin N; Fiscus SA; Nelson JA; Eron JJ; Kumwenda J
    AIDS; 2009 Jun; 23(9):1127-34. PubMed ID: 19417582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China.
    Liu P; You Y; Liao L; Feng Y; Shao Y; Xing H; Lan G; Li J; Ruan Y; Li D
    BMC Infect Dis; 2022 May; 22(1):426. PubMed ID: 35509014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.
    Salou M; Dagnra AY; Butel C; Vidal N; Serrano L; Takassi E; Konou AA; Houndenou S; Dapam N; Singo-Tokofaï A; Pitche P; Atakouma Y; Prince-David M; Delaporte E; Peeters M
    J Int AIDS Soc; 2016; 19(1):20683. PubMed ID: 27125320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
    Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
    BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
    Johnston V; Cohen K; Wiesner L; Morris L; Ledwaba J; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD
    J Infect Dis; 2014 Mar; 209(5):711-20. PubMed ID: 23943851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.
    Karade SK; Ghate MV; Chaturbhuj DN; Kadam DB; Shankar S; Gaikwad N; Gurav S; Joshi R; Sane SS; Kulkarni SS; Kurle SN; Paranjape RS; Rewari BB; Gangakhedkar RR
    Medicine (Baltimore); 2016 Sep; 95(37):e4886. PubMed ID: 27631260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
    Gregson J; Kaleebu P; Marconi VC; van Vuuren C; Ndembi N; Hamers RL; Kanki P; Hoffmann CJ; Lockman S; Pillay D; de Oliveira T; Clumeck N; Hunt G; Kerschberger B; Shafer RW; Yang C; Raizes E; Kantor R; Gupta RK
    Lancet Infect Dis; 2017 Mar; 17(3):296-304. PubMed ID: 27914856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: a prospective cohort study.
    Kan W; Teng T; Liang S; Ma Y; Tang H; Zuohela T; Sun G; He C; Wall KM; Marconi VC; Liao L; Leng X; Liu P; Ruan Y; Xing H; Shao Y
    BMJ Open; 2017 Sep; 7(9):e016012. PubMed ID: 28882911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Level of HIV Drug Resistance and Virologic Nonsuppression Among Female Sex Workers in Ethiopia: A Nationwide Cross-Sectional Study.
    Arimide DA; Amogne MD; Kebede Y; Balcha TT; Adugna F; Ramos A; DeVos J; Zeh C; Agardh A; Chih-Wei Chang J; Björkman P; Medstrand P
    J Acquir Immune Defic Syndr; 2022 Apr; 89(5):566-574. PubMed ID: 34966147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.